147 related articles for article (PubMed ID: 36176864)
1. Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study.
Patel N; Fayed M; Faldu P; Maroun W; Chandarana J
Cureus; 2022 Aug; 14(8):e28429. PubMed ID: 36176864
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
4. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
Lewis JR; Barre D; Zhu K; Ivey KL; Lim EM; Hughes J; Prince RL
J Bone Miner Res; 2014 Nov; 29(11):2489-97. PubMed ID: 24825180
[TBL] [Abstract][Full Text] [Related]
5. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
6. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
7. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus.
Ock M; Lee S; Kim H
J Clin Pharm Ther; 2022 Jul; 47(7):1028-1035. PubMed ID: 35257383
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.
Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL
Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930
[TBL] [Abstract][Full Text] [Related]
11. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
[TBL] [Abstract][Full Text] [Related]
12. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
[TBL] [Abstract][Full Text] [Related]
13. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
[TBL] [Abstract][Full Text] [Related]
14. Lower Trabecular Bone Score is Associated With the Use of Proton Pump Inhibitors.
Shin YH; Gong HS; Baek GH
J Clin Densitom; 2019; 22(2):236-242. PubMed ID: 30100220
[TBL] [Abstract][Full Text] [Related]
15. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
16. The relationship between proton pump inhibitor adherence and fracture risk in the elderly.
Ding J; Heller DA; Ahern FM; Brown TV
Calcif Tissue Int; 2014 Jun; 94(6):597-607. PubMed ID: 24706060
[TBL] [Abstract][Full Text] [Related]
17. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
[TBL] [Abstract][Full Text] [Related]
18. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
Targownik LE; Leslie WD; Davison KS; Goltzman D; Jamal SA; Kreiger N; Josse RG; Kaiser SM; Kovacs CS; Prior JC; Zhou W;
Am J Gastroenterol; 2012 Sep; 107(9):1361-9. PubMed ID: 22777336
[TBL] [Abstract][Full Text] [Related]
19. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
Khalili H; Huang ES; Jacobson BC; Camargo CA; Feskanich D; Chan AT
BMJ; 2012 Jan; 344():e372. PubMed ID: 22294756
[TBL] [Abstract][Full Text] [Related]
20. The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density.
Fattahi MR; Niknam R; Shams M; Anushiravani A; Taghavi SA; Omrani GR; Mahmoudi L
Risk Manag Healthc Policy; 2019; 12():349-355. PubMed ID: 31853206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
